Multi-center Study for Evaluating the Safety and Efficacy of the MedJ-01 Ridaforolimus Eluting Coronary Stent System (MedJ-01) In Coronary Stenosis Trial
Latest Information Update: 16 Mar 2023
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Angina pectoris; Coronary artery restenosis; Unstable angina pectoris
- Focus Therapeutic Use
- Acronyms JNIR
- Sponsors Medinol
- 14 Mar 2023 Status changed from active, no longer recruiting to completed.
- 05 Apr 2022 Planned End Date changed from 1 Feb 2022 to 1 Aug 2022.
- 26 Aug 2018 Status changed from recruiting to active, no longer recruiting.